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Aberrant epigenetic events contribute to tumorigenesis of all human cancers. Significant ef-
forts are underway in developing new generation of epigenetic cancer therapeutics. Al-
though clinical trials for agents targeting DNA hypermethylation and histone deacetylation
have yielded promising results, developing agents that target histone methylation remains
to be in the early stage. We and others have previously reported that 3-Deazaneplanocin A
(DZNep) is a histone methylation inhibitor that has a wide range of anticancer effects in vari-
ous human cancers. Here, focusing on acute myeloid leukemia (AML) as a model, we re-
ported a less toxic analog of DZNep, named D9, which is shown to be efficacious in AML
cell lines and patient-derived samples in vitro, as well as AML tumorigenesis in vivo. Gene
expression analysis in a panel of AML cell lines treated with D9 identified a set of genes that
is associated with D9 sensitivity and implicated in multiple oncogenic signaling pathways.
Moreover, we show that D9 is able to deplete the leukemia stem cells (LSC) and abolish
chemotherapy-induced LSC enrichment, leading to dramatic elimination of AML cell surviv-
al. Thus, D9 appears to be a robust epigenetic compound that may constitute a potential for
AML therapy.
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Introduction
Acute myeloid leukemia (AML) is an aggressive hematological disorder in which the haemato-
poietic progenitor cells lose their ability to differentiate normally and continue to proliferate.
AML is an extremely heterogeneous disease with variable long term survival rate ranging from
20%-90% [1]). Although a number of targeted therapeutics have been proposed for treating
AML, chemotherapy, such as cytarabine (Ara-C), adriamycin (ADR) or their combination, re-
mains to be the first-line treatment option for most of the AML patients [2, 3]. In spite of an
initial complete remission (CR) in nearly 70% of AML patients following the chemotherapy, a
large portion of these patients subsequently relapse and eventually die of the disease progres-
sion [4]. It is generally thought that the disease recurrence stems from a rare subset of leukemia
stem cells (LSCs) that are resistant to standard chemotherapy [5–8], which therefore raises a
strong need to develop therapeutics to target LSCs.
Although there are growing interests in developing epigenetic therapy for hematological
malignancies, the success for clinical advancement of histone deacetylase (HDAC) inhibitors
and DNA methylation inhibitors remains to be limited for AML. Additionally, aberrant his-
tone methylations, such as those induced by Polycomb protein Enhancer of Zeste homolog 2
(EZH2) [9, 10], Mixed-Lineage Leukemia (MLL) [11–13] and G9a [14–16] have been also
shown to be attractive therapeutic targets. To date, efforts for developing histone methylation
inhibitors are still in their infancy and no drugs have ever been approved by FDA or in late
stages of clinical trials in AML and other malignancies.
We have previously reported that S-adenosylhomocysteine hydrolase inhibitor 3-deazane-
planocin A (DZNep) is a potent histone methylation inhibitor that is able to deplete the onco-
genic PRC2 and associated histone H3 Lysine 27 trimethylation (H3K27me3) together with
other histone methylations and induce robust apoptosis in cancer cells but not in normal cells
[17]. Hereafter, there have been increasing numbers of reports showing the impressive antican-
cer effects of DZNep as a new epigenetic compound in a variety of cancer models both in vitro
and in vivo [18–23]. In particular, DZNep alone, or in combination with HDAC inhibitor, has
been shown to be effective in inducing growth arrest and apoptosis in AML cells [24, 25].
Therefore, there are interests in exploring DZNep and its analogs as a potential new class of
epigenetic cancer therapeutics for AML.
In this study, we reported a comprehensive study of a novel analog of DZNep, named D9, in
AML. We show that D9 induces strong growth inhibition and apoptosis in AML cells and its
sensitivity in AML cells is associated with its ability to modulate gene expression associated
with multiple oncogenic signaling pathways. Importantly, D9 is able to deplete both the basal
and chemotherapy-enriched LSCs, and abrogate chemotherapy-induced gene expression asso-
ciated with chemoresistance. Our results demonstrated a unique utility of D9 as a novel histone
methylation inhibitor in targeting both bulk leukemic cells and leukemia stem cells (LSCs),
thus providing a novel potential for eradication of AML.
Materials and Methods
Cell culture and drugs
A panel of acute myeloid leukemia (AML) cell lines, that is, MV4-11, Kasumi-1, KG-1, KG-1a,
TF-1, TF-1a, MOLM-14, THP-1, HL-60 and Mono-Mac-1 was obtained as described previous-
ly [24]. D9 (MW: 308.16) was synthesized at Institute of Chemical and Engineering Sciences,
Singapore. Suberoylanilide hydroxamic acid (SAHA), Adriamycin, Ara-C and Decitabine were
purchased from Sigma-Aldrich.
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Patient samples
Frozen bone marrow (BM) blasts from newly diagnosed AML patients were obtained at the Na-
tional University Hospital in Singapore with informed consent and approved by Institutional
Review Board of National University Hospital. Written consents were obtained from the partici-
pants. Immediately after recovery, primary AML cells were cultured in IMDM supplemented
with 10% FBS (Invitrogen), FLT3 ligand (20 ng/ml), SCF (20 ng/ml), IL-3 (20 ng/ml), G-CSF
(50 ng/ml) and thrombopoietin (TPO; 50 ng/ml) (R&D Systems).
Cell viability assay
Cells were seeded at a density of 1 × 103 cells per well of 96-well optical bottom plate (Corning)
24 hours before D9 treatment. A range of concentrations of D9 diluted with basal RPMI or
IMDMmedium (Invitrogen) were added into the wells of cell suspension and incubated for 96
hours before detection. Six replicas were conducted for each sample. CellTiter-Glo Luminescent
Cell Viability Assay (Promega) was used to evaluate the viable cell numbers. The luminescence
signal was measured by MicroLumat Plus LB96V system (BERTHOLD TECHNOLOGIES). To
calculate EC50, nonlinear regression sigmoidal dose response curves were generated using Graph-
Pad PRISM3.
Transwell migration and invasion assay
For invasion assay, 24-well Falcon FluoroBlok Transwell inserts (BD Biosciences) with a pore
size of 8 μmwere precoated with growth factor-reduced Matrigel (BD Biosciences) for 3–4
hours at 37°C before seeding the cells. For migration assay, the coating step was omitted.
5 × 104 pretreated cells in 200 μl RPMI containing 0.25% FBS were seeded into the upper
chamber of each insert. 750 μl RPMI containing 10% FBS were added outside the chamber as
chemoattractant. Inserts were fixed after 24 hours of incubation at 37°C by using 3.7% formal-
dehyde for 20 minutes at room temperature. After several washes, the inserts were stained with
25 μg/ml propidium iodid for 30 minutes at room temperature in the dark. The migrated and
invaded cells in 10 individual fields beneath the inserts were scanned and counted with Cello-
mics ArrayScan VTI (Thermo Scientific.). Triplicates were conducted for each sample, and at
least three independent experiments were performed.
Cell adhesion assay
96-well optical bottom plates were coated with 10 μg/ml Fibronectin (Sigma-Aldrich) for over-
night at 4°C. The plates were washed three times using PBS prior to seeding the cells. 1 × 103
TF-1a cells were seeded into each well and treated with D9 (100 nM) with or without Ara-C
(50 nM). After 72 hours, the wells were gently washed by PBS three times to remove the unat-
tached cells. CellTiter-Glo Luminescent Cell Viability Assay (Promega) was used for the quan-
tification of the remaining adherent cells.
Antibodies
The following primary antibodies were used. Cleaved PARP, EZH2, p-ERK (T202/204), p-
AKT (S473), total ERK and total AKT (Cell Signaling Technology); Bim and Survivin (BD Bio-
sciences); H3K27me3, H3K9me3, H3K4me3, H3K79me2, H4K20me3 and total H3 (Upstate
Biotechnology); and actin (Sigma-Alrich) were used as primary antibodies. Anti-rabbit and
anti-mouse horseradish peroxidise linked whole antibodies (GE Healthcare) were used as
secondary antibodies.
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PI staining, active caspase3 staining and flow cytometric analysis
Treated cells were washed twice with cold PBS before fixing by 70% ethanol for at least 1 hour
at 4°C. The fixed cells were washed twice with PBS, treated by 100 μl RNase (100 μg/ml) for 5
minutes, and then stained with 400 μl propidium iodide (PI) (50 μg/ml) for 30 minutes in the
dark. The DNA contents were measured by FACSCalibur (Becton Dickson Instrument), and
1 × 104 cells from each sample were analyzed by using Cell Quest software (Becton Dickinson
Instrument). For active caspase3 assay, cytofix/cytoperm fixation/permeabilization kit (BD
Biosciences) coupled with FITC rabbit anti active Caspase-3 antibody (BD Biosciences) were
used to stain the cells for flow cytometric analysis.
Immunofluorescent staining and flow cytometric analysis
TF-1a Cells were stained with CD38-FITC antibody and CD34-APC antibody (Miltenyi Bio-
tec) sequentially. After staining, the cell pellets were suspended with 0.5 ml of 1 μg/ml propi-
dium iodide (PI) just before harvested for analysis by FACSCalibur (BD Bioscience). Cell
debris and dead cells were excluded from the analysis based on scatter signals and PI fluores-
cence. The stained cells were analyzed by using CellQuest software (BD bioscience).
Microarray gene expression analyses and RT-PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen). Microarray hybridization was
performed using Human HT-12 V4.0 expression beadchip (Illumina), and data analysis was
performed using GeneSpring GX (Agilent Technologies). The finalized genesets were imported
into Ingenuity Pathway Analysis (IPA) (www.ingenuity.com) for gene ontology analysis. The
microarray data reported herein have been deposited at the National Centre for Biotechnology
Information’s Gene Expression Omnibus (accession no. GSE59624 and GSE59625). Reverse-
transcription and quantitative PCR (qPCR) assays were performed using the High-Capacity
cDNA Archive Kit and Kapa SyBr Fast qPCR Kit (Kapa Biosystems), respectively. Primer se-
quences are listed in S1 Table.
Mouse xenografts and drug treatment
For subcutaneous implantation, 5 x 106 MOLM-14 cells were subcutaneously injected into female
athymic BALB/c nude mice (5–8 week-old). D9 at three different doses (30, 60 and 90 mg/kg)
was administered though intraperitoneal (i.p.) injection as qd x 5d/w for 3 weeks in these recipi-
ents. Tumor diameters were measured every 3–4 days with calliper and the body weight of mice
was monitored overtime. For bone marrow engraftment, 1 x 106 MOLM-14 cells were trans-
planted into the sublethally irradiated NOD/SCIDmice (5–8 week-old) mice through lateral tail
vein injection. D9 (60 mg/kg) was administered through intraperitoneal (i.p.) injection two days
after the tumor engraftment as q2d/w for 3 weeks. All animal studies were conducted in compli-
ance with animal protocols approved by the ASTAR-Biopolis Institutional Animal Care and
Use Committee (IACUC) of Singapore.
Statistical analysis
Statistical analysis of this study was performed using GraphPad PRISM3. All values are ex-
pressed as mean ± SEM (standard error of mean) of at least three independent experiments.
P values were calculated with the two-tailed Student’s t test. A p value< 0.05 is considered
statistically significant.
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Results
EC50 profiling of D9 in human cancer cell lines
In an effort to identify DZNep analogs with better potency and safety profile, we have synthe-
sized a series of DZNep-like compounds and identified several lead compounds through
structure and cellular activity relationship (SAR) analysis as well as correlation of chemical
and physical properties. One such compound, D9 (Fig 1A), showed a comparable cellular ac-
tivity with DZNep but a 20-fold less toxicity in mice [26] and was thus chosen for further
investigations.
We first set out to determine which type of cancer cells will be most sensitive to D9. To do
this, we screened a large panel of human cancer cell lines, including 32 solid tumor cell lines and
80 blood cancer cell lines, and determined their EC50 responses to D9. Overall, these cancer cell
lines showed heterogeneous responses to D9; and blood cancer cell lines in general appeared to
be more sensitive to D9 compared to solid tumor cell lines (median EC50 of 3.14 μM in blood
cancer cell lines versus 25.1 μM in solid tumor cell lines) (Fig 1Bi and 1Bii; S2 and S3 Tables).
Among the blood cancer cell lines, a significant number of AML cell lines such as MV4-11, HL-
60, EOL1, and GDM-1 were highly sensitive to D9, with EC50s of< 1μM (Fig 1Bii). We thus de-
cided to focus on AML for further investigation of the anti-cancer effect of D9.
In vitro activity of D9 in AML cell lines
To investigate the effect of D9 on AML, we further validated the effect of D9 on the short-term
viability of a panel of 10 well-established AML cell lines. For comparison, we also included his-
tone deacetylase (HDAC) inhibitor SAHA and DNAmethylation inhibitor Decitabine, both of
which are FDA approved for the treatment of hematological malignancies [27, 28]. The results
showed that in general AML cell lines were remarkably more sensitive to D9 compared to ei-
ther SAHA or DAC, with a median EC50 of 0.31 μM for D9, 1.08 μM for SAHA and 0.94 μM
for DAC, respectively (Fig 2B and 2C), indicating that D9 is potentially a more potent com-
pound in AML cell lines compared to SAHA and DAC. Moreover, in a 14-day long soft agar
colony formation assay, D9 was also effective in reducing the colony growth of MOLM-14,
KG-1 and HL-60 cells in a dose-dependent manner, with similar EC50s as determined by the
short-term cell viability assay (Fig 2D). Finally, we show that D9 was able to induce a sub-G1
cell death in MV4-11, MOLM-14, TF-1, KG-1, Kasumi-1 and TF-1a cells (45–75%), but to less-
er extents in THP-1, HL-60, Mono-Mac-1and KG-1a cells (< 20%) (Fig 2E). The D9-induced
cell death was further confirmed to be apoptosis by measuring Caspase 3 activation in MOLM-
14 and MV4-11 cells (Fig 2F).
Effects of D9 on histone methylation and transcriptome changes
associated with D9-induced apoptosis in AML cells
We next evaluated the overall effects of D9 on histone lysine methylations in sensitive MOLM-
14 and resistant KG-1a to determine if D9 would have differential effects on the histone meth-
ylations in the two cell lines. In both cell lines we showed that D9 induced similar levels of sup-
pression of H3K27me3 and H4K20me3 and to lesser extents on H3K4me3 and H3K79me2,
while it had little effects on H3K9me2 and H3K9me3 (Fig 3A and 3B). This observation is simi-
lar to the parental compound DZNep that has been shown to act as a selective but non-specific
histone methylation inhibitor in cancer cells, including AML [17, 24]. Thus, the differential
sensitivities of AML cells to D9 do not seem to be associated with its ability to inhibit the bulk
histone methylation per se, but perhaps more likely to be associated with the differential gene
expression response to D9.
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To test this hypothesis, we treated three sensitive (MOLM-14, MV4-11 and TF-1) and three
resistant (Mono-Mac-1, THP-1, and KG-1a) cell lines with D9 for 48 hours and performed
Illumina BeadChip transcriptom profiling analysis. Significance Analysis of Microarrays
Fig 1. EC50 profile of D9 in human cancer cell lines. (a) Chemical structure of D9. (b) Bar graphs showing EC50 of D9 measured in a panel of solid (bi)
and blood (bii) cancer cell lines using cell viability assay.1 x 10^3 cells of individual cell lines were seeded into 96-well plates in triplicates and D9 at 10
different doses was added 24 hours post cell seeding. Proliferation was measured after 96 hours treatment of D9 using an ATP based cell viability assay.
EC50 of D9 was calculated by nonlinear regression (curve fit) using GraphPad PRISM3. Data represent the means of EC50 of D9 measured in three
independent experiments, with each experiment run in triplicates.
doi:10.1371/journal.pone.0122983.g001
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Fig 2. In vitro anti-leukemia activity of D9 in AML cell lines. (a) Bar graph showing EC50 of D9 measured in a panel of AML cell lines using cell viability
assay. (b) Dot plot showing EC50 of D9, SAHA and DACmeasured in the same panel of AML cell lines. The short lines represent the median EC50 of each
compound in the AML cell line panel. (c) Table showing EC50 of D9, SAHA and DACmeasured in the AML cell line panel. (d) Representative images of soft
agar assay conducted in MOLM-14, KG-1 and HL-60 cells. 1 x 10^3 cells were mixed with D9 at various doses in semi-solid media and incubated for 2 weeks.
Colony growth was assessed and EC50 of D9 measured by soft agar assay was indicated in the brackets. Data represent the means of EC50 of D9
measured in three independent experiments, with each experiment run in triplicates. (e) Bar graphs showing sub-G1 percentage of 10 AML cell lines treated
with indicated concentrations of D9 for 72 hours, followed by propidium iodide (PI) staining and fluorescence-activated cell sorting (FACS) analysis. (f) Bar
graphs showing the percentage of cells positive for active Caspase 3 in MOLM-14 and MV4-11 cells treated with indicated concentrations of D9 for 72 hours,
Therapeutic Effects of DZNep Analog D9 on AML
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(SAM) analysis shows that D9 treatment resulted in transcriptional changes of 547 genes, in-
cluding 327 upregulated genes and 220 downregulated genes in sensitive cell lines but not in re-
sistant cell lines, as shown in a heatmap of supervised gene clustering (Fig 3C; S4 and S5
Tables). Ingenuity pathway analysis (IPA) of both gene sets revealed gene networks linked to
the PI3K/AKT and MEK/ERK pathways (Fig 3Di and 3Dii), whose aberrant activation is fre-
quently observed in AML [29, 30]. This analysis raised the possibility that D9 treatment in-
duced a transcriptional change that may result in modulations of PI3K/AKT and MAPK
signaling cascades in D9-sensitive cell lines but not resistant cell lines.
D9 treatment suppresses PI3K and MAPK signaling in both AML cell
lines and primary patient samples
To validate the above hypothesis, we investigated the effects of D9 on the PI3K and MAPK
pathways by western blot analysis in two most sensitive cell lines MOLM-14 and MV4-11 and
three resistant cell lines Mono-Mac-1 (MM), THP-1 and KG-1a. Consistent with what we have
predicted from the gene expression analysis, D9 treatment resulted in significant suppression
of MAPK and PI3K signaling as indicated by reduced phosphorylation of ERK (T202/204) or
AKT (S473) in sensitive MOLM-14 and MV4-11 cells at both 24 and 48 hours without affect-
ing the total levels of either ERK or AKT (Fig 4A). In contrast, the three resistant cells did not
show such changes on p-ERK (T202/204) or p-AKT (S473) (Fig 4A).
It is well known that ERK inhibition results in upregulation of pro-apoptotic Bim induction
[31, 32]. Accordingly, we found that all the three Bim isoforms, in particular BimS, the most
potent isoform for apoptosis [33], were upregulated by D9 in sensitive lines but not in resistant
lines. On the other hand, expression of the anti-apoptotic molecule, Survivin, which is a down-
stream effector of AKT [34, 35], was suppressed by D9 only in the sensitive cell lines (Fig 4B).
Thus, the combined changes in Bim and Survivin induced by D9 are consistent with the strong
apoptosis observed in the sensitive cell lines. Based on these observations, we proposed that the
molecular mechanisms underlying the D9 sensitivity in AML cells is associated with a tran-
scriptomic response resulting in downregulation of oncogenic PI3K-AKT and MAPK signaling
pathways, leading to apoptosis.
To validate the clinical relevance of these findings, we investigated whether D9 has a similar
effect on patient-derived primary AML cells. To this end, we managed to test the effect of D9
on 4 sets of primary AML blasts isolated from four newly diagnosed AML patients. The result
shows that the primary blasts, like AML cell lines, exhibited heterogeneous responses to D9,
with EC50 of D9 ranging from 0.96 to 13.43 μM (Fig 4Cii and S6 Table). In the sensitive patient
sample AD353, we detected a robust PARP cleavage and strong reductions of phosphorylated
AKT and ERK, which was similar to MOLM-14 line included here as a positive control. In con-
trast, we did not see such changes in resistant AD409 sample. In fact, we even observed a slight
activation of AKT and ERK signaling in AD409 (Fig 4Ciii), probably a result of a feedback acti-
vation. Thus, D9 is able to target multiple oncogenic signaling pathways and this effect seems
to be associated with the therapeutic effect in sensitive AML cells sourced from both the cell
lines and patient-derived primary cells.
followed by active Caspase 3 antibody staining and FACS analysis. Data are mean ± SEM; N = 3; *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two tailed
t test.
doi:10.1371/journal.pone.0122983.g002
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Fig 3. Effects of D9 on histonemethylation and transcriptome in AML.Western blot analysis showing
the level of cleaved PARP, EZh2 and a series of histone lysine methylation marks in MOLM-14 (a) and KG-1a
cells (b) treated by D9 at indicated concentrations for 48 and 72 hours. (c) Heat map of differential genesets
between sensitive and resistant cell lines with D9 treatment. Three sensitive (MOLM-14, MV4-11 and TF-1)
and three resistant cell lines (Mono-Mac-1, KG-1a and THP-1) were treated with D9 at 1 or 5 μM for 48 hours.
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D9 inhibits AML tumorigenesis in vivo
To evaluate the therapeutic potential of D9 in vivo, we used both the xenograft tumor growth
model and bone marrow engraftment model. First, in a model of MOLM-14-derived subcuta-
neous transplantation in nude mice, D9 administered daily at 30, 60 and 90 mg/kg though
intraperitoneal (i.p.) injection resulted in marked inhibition of tumor growth in a dose-depen-
dent manner (Fig 5Ai). The treatment did not cause overt signs of toxicity as judged by insig-
nificant body weight loss of mice before and after the D9 treatment (Fig 5Aii), suggesting that
the effective doses of D9 were well tolerated in the recipient mice.
We next determined the anticancer efficacy of D9 in a more therapeutically relevant model
of AML, in which MOLM-14 cells were injected through the tail vein of sublethally irradiated
NOD/SCID mice to induce leukemic dissemination and mortality. We found that D9 given at
60 mg/kg through i.p. injection caused dramatic reduction in leukemic burden (data not
shown) and significant prolonged life span of recipient mice (median survivals of 42 days in
D9 group vs. 36 days in control group, p< 0.001) (Fig 5Bi). Again, D9 in this model was also
well tolerated and no overt toxicity was observed in recipient mice (Fig 5Bii). Collectively, our
results showed that D9 possessed potent anti-AML effects both in vitro and in vivo.
D9 treatment depletes both basal and chemotherapy-induced LSC
Because tumor initiating cells or cancer stem cells have been thought to have undergone epige-
netic reprogramming [36, 37], we sought to determine if D9 as a histone methylation inhibitor
would be effective in targeting AML leukemia stem cells (LSCs). To test the effect of D9 on
LSCs, we used TF-la, an AML primitive myeloid progenitor cell line, which has a high fraction
of stem-like CD34+CD38- cells and thus considered as an excellent model for studying LSC
[38]. Treatment of TF-1a cells with increasing low nanomolar concentration of D9 for 72
hours resulted in efficient depletion of CD34+CD38- population (Fig 6A). For a comparison,
we also included HDAC inhibitor SAHA and DNAmethylation inhibitor DAC in this experi-
ment. Interestingly, we did not observe such an effect for SAHA and DAC (Fig 6B).
Chemotherapy is well known to induce enrichment of cancer stem cell, which is believed to
cause chemoresistance and disease recurrence. We next tested if D9 is able to reduce chemo-
therapy-induced LSC enrichment. As expected, both Ara-C and ADR treatment of TF-1a cells
for 72 hours resulted in dramatic increases of CD34+CD38- populations, while co-treatment
with D9 (100 nM) nearly completely abrogated such increases (Fig 6B and 6C). Moreover, in a
14 days long-term experiment, D9 used even at 20 nM was also able to sufficiently deplete the
CD34+CD38- enrichment by Ara-C (Fig 6D). Again, SAHA did not show such an effect to an-
tagonize the chemotherapy-induced LSC enrichment, while DAC showed a much weaker effect
than D9 in targeting LSC (Fig 6E).
To further evaluate the effects of D9 in the context of LSC survival associated with chemore-
sistance, we used a colony-forming-unit (CFU) assay, a gold standard in vitro assay to evaluate
a long term survival of haematopoietic or leukemia stem/progenitor cells. In this experiment,
TF-1a cells were treated with Ara-C or ADR, and then the dead cells were removed by using
Dead Cell Removal Kit and the remaining live cells were seeded with equal numbers for CFU
assay. Consistent with the induction of LSC by chemotherapy, we observed more colonies
formed in Ara-C- or ADR-treated cells compared to untreated control (Fig 6F). Strikingly, co-
Total RNA was isolated for microarray and SAM analysis. 327 genes were up-regulated and 220 genes were
down-regulated upon D9 treatment in sensitive cells relative to resistant cells using 10% false discovery rate
(FDR) cut-off. (d) Ingenuity Pathway Analysis (IPA) of differentially up-regulated geneset and down-regulated
geneset (dii) showing their strong connections to PI3K/AKT and MEK/ERK signaling pathways.
doi:10.1371/journal.pone.0122983.g003
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treatment with D9, but not SAHA, nearly completely abolished the colony formation induced
by Ara-C or ADR (Fig 6F). Under the same condition, DAC exerted comparable inhibitory ef-
fect on the colony formation of TF-1a cells (Fig 6F). These findings further suggest that D9 as a
histone methylation inhibitor is equipped with a special ability to remove LSC and thus the
chemoresistance in AML.
Fig 4. Effects of D9 on AKT and ERK phosphorylation in AML. (a)Western blot analysis of p-ERK (T202/
204), total ERK, p-AKT (S473), total AKT and ACTIN in indicated AML cell lines treated with D9 for 24 hours
and 48 hours. (b) Western blot analysis showing the effects of D9 on Bim and Survivin in AML cell lines as in
(a). (c) The frozen primary AML patient blasts were recovered for 24 hours and the dead cells were removed
using Dead Cell Removal Kit just before D9 treatment. The blasts were treated for 96 hours for cell viability
assay and 48 hours for western blot analysis. The diagrams showed the drug response curves of AML patient
blasts towards D9 (ci), measurement of EC50 of D9 using cell viability assay (cii) and western blot analysis of
PARP, p-ERK (T202/204), total ERK, p-AKT (S473), total AKT and ACTIN in AML patient blasts as well as
MOLM-14 with and without D9 treatment (ciii). Each data point in the plots of drug response curves of D9
represents the mean ± SEM of six replicates at each specified concentration of D9, N = 3.
doi:10.1371/journal.pone.0122983.g004
Fig 5. In vivo effects of D9 in AMLmousemodels. (a) Subcutaneous xenograft tumor growth of MOLM-14
cells in Balb/c mice treated with D9. 5 x 10^6 of MOLM-14 cells were injected into mice subcutaneously (s.c.).
D9 at three different doses (30, 60 and 90mg/kg) was administered through intraperitoneal (i.p.) injection as
qd x 5d/w for 3 weeks in these recipients from day 8 to day 23 after transplantation, with vehicle treatment as
control. The graphs show the tumor sizes (ai) and body weight change (aii). Data are mean ± SEM,
***P < 0.001, unpaired two tailed t test. (b) Kaplan–Meier curves of NOD/SCIDmice treated with D9. 1 x 10^6
of MOLM-14 cells were injected into sublethally irradiated NOD/SCIDmice through tail vein. D9 at 60mg/kg
was administered through i.p. injections as q2d/w for 3 weeks in these recipients from day 2 after
transplantation, with vehicle treatment as control. The graphs showed the survival rate (bi) and body weight
change (bii) during D9 treatment. Data are mean ± SEM, ***P <0.001, log-rank (Mantel-Cox) test conducted.
doi:10.1371/journal.pone.0122983.g005
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Fig 6. Effective anti-leukemia stem cells (LSC) activity of D9 in AML. (a) Bar graphs showing FACS analysis of the proportion of CD34+CD38- population
in TF-1a after the single treatment with D9, SAHA or DAC for 72 hours. (b) Representative FACS histogram profiles of CD34+CD38- cell population in TF-1a
cells treated with D9 (100 nM) alone or in combination with either Ara-C (20 nM) or ADR (50 nM). (c) Bar graphs showing the proportion of CD34+CD38-
population in TF-1a cells treated as in B. (d) Bar graphs showing the proportion of CD34+CD38- population in TF-1a treated with D9 (20 nM) with or without
Ara-C (20 nM) for 14 days. (e). Bar graphs showing the percentage of CD34+CD38- cell population in TF-1a cells treated as indicated. (f) Colony Formation
Unit (CFU) assay showing the effects of D9, SAHA or DAC on basal or Ara-C or ADR-induced colony formation capacity of TF-1a cells. The medium and
drugs were replenished every 3 to 4 days and the dead cells were removed by Dead Cell Removal Kit. 1 x 10^3 live cells were seeded with semi-solid colony
formation medium and incubated for 2 weeks before enumeration. Representative images of the colony formation of TF-1a were shown on (fi) and bar graphs
were shown the colony numbers on (fii). Data are mean ± SEM; N = 3; *P < 0.05, **P < 0.01, ***P < 0.001, ns represents no significance, unpaired two
tailed t test.
doi:10.1371/journal.pone.0122983.g006
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D9 abolishes chemotherapy-induced gene expression associated with
drug resistance in AML
We next sought to characterize the molecular changes induced by the chemotherapy that is an-
tagonized by D9. To do this, TF-1a cells were treated with Ara-C or ADR or co-treated with
D9 were harvested. Total RNA was isolated and subjected to gene expression analysis. A super-
vised gene cluster analysis revealed a common set of 720 genes that are induced by both Ara-C
and ADR but repressed by D9 (Fig 7A and S7 Table). Ingenuity Pathway Analysis (IPA) indi-
cates that the gene categories including “Cellular Movement” and “Cell-To-Cell Signaling and
Interaction” appeared among the top five Bio Functions (Fig 7B). In addition, among the top
ten canonical pathways which were significantly associated with chemotherapeutic gene re-
sponse, “Leukocytes Extravasation Signaling”, “IL-8 Signaling” and “Integrin Signaling” were
of particular interests as they have been previously linked to AML tumorigenesis (Fig 7C). In
particular, the network analysis indicated the involvements of integrins-AKT signalling in che-
motherapy induced gene changes (Fig 7D). Our microarray data showed that multiple mem-
bers of integrins were upregulated by Arac, which were abolished by co-treatment with D9.
The same was also observed for multiple ECM ligands of integrins, particularly the laminin
family members, and numerous cytokines and their respective receptors, all well known to be
associated with cancer progression, self-renewal and drug resistance (Fig 7E, S8–S11 Tables).
The microarray results were further validated by quantitative RT-PCR analysis of 15 represen-
tative genes of the implicated gene categories (Fig 7F).
Furthermore, in consonance with the above molecular changes, we noticed that Ara-C treat-
ment induced an emergence of a small proportion of TF-1a cells that were attached to the tis-
sue culture plate and exhibited spread and mesenchymal-like morphology, which was
reversible upon D9 treatment (Fig 7G). We also found that Ara-C triggered a significant num-
ber of migratory, invasive and adherent cells, which were effectively abolished by D9 but not by
SAHA. While DAC exerted much weaker effects compared with D9 (Fig 7H, 7I and 7J). These
results showed that D9 is able to inhibit the enhanced migration, invasion and adhesion capaci-
ties of AML cells induced by chemotherapy. Collectively, these findings demonstrated the po-
tential ability of D9 to target chemoresistance of AML through modulating a wide range of
gene sets functionally important in LSC self-renewal, invasion and tumor dissemination.
Discussion
AML is the most common leukemia of adults, and its incidence increases with age. Although
chemotherapy is capable of producing complete remission in almost 70% of patients, many of
them will ultimately relapse and succumb to their disease. Thus, there is a great need of new
treatment strategies for AML.
In this study, we provide a comprehensive preclinical investigation of D9, an analog of his-
tone methylation inhibitor DZNep in AML. DZNep is a SAM hydrolase inhibitor that inhibits
multiple histone methylations and is able to effectively deplete oncogenic PRC2 protein com-
plex and associated H3K27me3. DZNep has been shown to be effective in inducing apoptosis
in a variety of cancer cells both in vitro and in vivo and has been used as a useful tool for study-
ing EZH2-mediated gene silencing. In contrast, the specific catalytic inhibitors of EZH2, such
as GSK126 or GSK343, though potent in killing some hematological malignant cells such as the
diffuse large B-cell lymphoma (DLBCL) that carry EZH2 activating mutations [10, 39], do not
seem to be effective in cancer cells overexpressing a wild type EZH2 and only have a modest ef-
fect, if any, on EZH2 target gene expression [9, 40].
Like DZNep, D9 inhibits multiple histone methylation marks such as H3K27me3 and
H4K20me3 and also depletes EZH2 protein expression in AML cell lines, which was
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Fig 7. D9 targets cell adhesion-mediated drug resistance (CAM-DR) in AML. (a) Heat map of 720
genesets induced by both Ara-C and ADR which were suppressed by D9. (b) The diagram showing the top
five Bio Functions of commonly upregulated 720 genes by Ara-C and ADR suggested by IPA. (c) The
diagram showing the top ten canonical pathways of commonly upregulated 720 genes by Ara-C and ADR
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accompanied by effective growth inhibition and apoptosis in both AML cell lines and primary
AML cells. It also has a potent anti-tumor effect in vivo with a low level of toxicity. However,
the mechanisms governing the pharmacologic response are certainly more complex as the
above mentioned changes were seen in both sensitive and resistant AML cell lines. Rather, we
believe that the intrinsic differences of AML cells in transcriptional response to the chromatin
changes induced by D9 may be responsible for the differential sensitivity to D9. Indeed, we
identified gene expression changes that are associated with D9 sensitivity/resistance in AML
and these changes indicate the downregulation of a number of key oncogenic pathways and in-
duction of apoptosis, which was validated in both cell lines and primary samples of AML.
Thus, the histone methylation inhibitor D9 has produced epigenetic changes that blunted mul-
tiple oncogenic signaling pathways in AML simultaneously. Despite the complexity, this actu-
ally may provide a much desired advantage in treating cancer cells. Moreover, the molecular
changes in p-AKT (S473) and p-ERK (T202/204) as well as the upregulation of Bim and the
downregulation of Survivin in response to D9 in an ex vivo test might serve as surrogate mark-
ers for evaluating patient’s response to D9 or similar compounds in the future.
A key finding in our study is the observed effect of D9 on leukemia stem cells. This involves
the stem-like CD34+CD38- cells in AML which can be induced by chemotherapy. The effect of
D9 on chemotherapy-induced CD34+CD38- LSC population correlated well with its ability to
deplete the colony forming capacity of LSCs when combined with chemotherapy. It is impor-
tant to note that in these experiments D9 given at a low nanomolar concentration is sufficient
to deplete the LSCs and overcome the chemoresistance, suggesting a potential therapeutic ben-
efit of D9 when combined with chemotherapy in treating AML patients.
Mechanistically, we show that the transcriptional gene expression response in which a large
number of genes implicated in cancer stemness, EMT, inflammation, migration and drug resis-
tance are induced by chemotherapy but abolished by D9. In particular, a group of adhesion
molecules and their corresponding ligands, multiple cytokines, chemokines, as well as EMT re-
lated genes were markedly induced by Ara-C but prevented by D9 co-treatment, which is con-
sistent with the phenotypic changes showing that D9 significantly abrogated the EMT-like
conversion as well as increased cell adhesion, migration and invasion following the chemother-
apeutic treatment. Numerous studies reported that epithelial-mesenchymal transition [41]
cross-talks with metastasis, cancer stem cell and drug resistance [41–44]. Moreover, accumu-
lated evidence suggests that leukemic stem cells (LSCs) in contact with bone marrow (BM)
stromal cells and extracellular matrix (ECM) components may acquire resistance to chemo-
therapy by a process known as cell adhesion-mediated drug resistance (CAM-DR) [45, 46].
Thus, we propose that AML treated with chemotherapeutic agent like Ara-C may utilize the
similar mechanism for disease dissemination. The successful mitigation of CAM-DR by D9
suggested the therapeutic potential of D9 to target chemoresistance and AML recurrence.
We also compared D9 with two other FDA approved epigenetic drugs, HDAC inhibitor
SAHA and DNAmethylation inhibitor DAC in various anti-cancer aspects in AML cell line
suggested by IPA. (d) The diagrams showing Integrins and AKT are highly associated networks of commonly
upregulated 720 genes by Ara-C and ADR suggested by IPA. (e) Bar graphs showing the averaged values of
46 probes of Integrin members, 24 probes of Laminins, 8 probes of cytokines and 8 probes of receptors of
cytokines extracted from normalized microarray data of CD34+CD38- double-selected TF-1a cells treated as
in A. (f) Bar graphs showing qRT-PCR validation of microarray expression data of 15 representative genes as
indicated. (g) Representative phase-contrast images of TF-1a cells treated with D9 (100 nM), Ara-C (50 nM)
alone or combination. Bar graphs showing transwell migration assay (h), invasion assays (i) and adhesion
assay (j) conducted on TF-1a cells treated with D9 (100 nM), SAHA (100 nM) or DAC (100 nM) with or without
Ara-C (100 nM). Data are mean ± SEM; N = 3; *P < 0.05, **P < 0.01, ***P < 0.001, ns represents no
significance, unpaired two tailed t test.
doi:10.1371/journal.pone.0122983.g007
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model. Of significant notice is that our results demonstrated D9 was more potent to suppress
AML than SAHA and DAC. Thus, these findings demonstrated a special utility of this class of
histone methylation inhibitors for treating AML.
In conclusion, we show that D9 may represent a new generation epigenetic compound that
is capable of exerting multifactorial anti-cancer activities including inhibiting multiple onco-
genic signaling pathways, targeting LSC and chemoresistance. Regardless of the exact mecha-
nism of D9, its intriguing anti-cancer effects make it a promising cancer drug candidate for
further investigation.
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